Akebia Therapeutics

After breakup with Otsuka, Akebia finds new partner for oral anemia drug in Europe
After breakup with Otsuka, Akebia finds new partner for oral anemia drug in Europe
Fierce Pharma
Akebia Therapeutics
Medice Arzneimittel Pütter
Europe
Australia
Vafseo
chronic kidney disease
Flag link:
Akebia's Appeal for Anemia in CKD Drug Delayed Again
Akebia's Appeal for Anemia in CKD Drug Delayed Again
BioSpace
Akebia Therapeutics
vadadustat
chronic kidney disease
Flag link:
Sometimes, Clinical Trials Miss the Mark: Neurocrine, Akebia, Eliem and Athira
Sometimes, Clinical Trials Miss the Mark: Neurocrine, Akebia, Eliem and Athira
BioSpace
clinical trials
Neurocrine Biosciences
Akebia Therapeutics
Eliem Therapeutics
Athira Pharma
Flag link:
In a one-two gut punch after kidney drug CRL, Akebia slapped with partial hold and will lay off 42% of staff
In a one-two gut punch after kidney drug CRL, Akebia slapped with partial hold and will lay off 42% of staff
Endpoints
Akebia Therapeutics
FDA
vadadustat
layoffs
Flag link:
FDA rejects Akebia drug, dealing another blow to anemia pills
FDA rejects Akebia drug, dealing another blow to anemia pills
BioPharma Dive
Akebia Therapeutics
vadadustat
FDA
chronic kidney disease
anemia
Flag link:
Akebia tries for FDA approval of anemia drug after mixed data
Akebia tries for FDA approval of anemia drug after mixed data
BioPharma Dive
Akebia Therapeutics
anemia
FDA
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
$1.3 Billion Merger Between Akebia Therapeutics and Keryx Biopharmaceuticals to Focus on Kidney Disease
$1.3 Billion Merger Between Akebia Therapeutics and Keryx Biopharmaceuticals to Focus on Kidney Disease
CP Wire
Akebia Therapeutics
Keryx
kidney disease
M&A
vadadustat
Flag link:
$1.3 Billion Merger Between Akebia Therapeutics and Keryx Biopharmaceuticals to Focus on Kidney Disease
Akebia Therapeutics
Keryx
kidney disease
Flag link:
Merrimack employee accused of leaking clinical trial data
Merrimack employee accused of leaking clinical trial data
Fierce Biotech
Merrimack
clinical trials
clinical trial data
Akebia Therapeutics
SEC
Flag link:
Biotech employee charged with insider trading based on study results
Biotech employee charged with insider trading based on study results
Stat
insider trading
biotech
Akebia Therapeutics
Flag link:
This Past Week’s Top 5 Biotech Movers
This Past Week’s Top 5 Biotech Movers
24/7 Wall St
biotech
Akebia Therapeutics
Clovis Oncology
Mirati Therapeutics
Vivus
Vitae
Flag link:
​Here’s the deal with Akebia’s anemia drug that caused a 50% stock hike today
​Here’s the deal with Akebia’s anemia drug that caused a 50% stock hike today
Bizjournals.com
Akebia Therapeutics
anemia
vadadustat
kidney disease
Flag link:
Akebia, MediWound Post Gains Following IPOs
Akebia, MediWound Post Gains Following IPOs
Wall St 24/7
Akebia Therapeutics
IPOs
MediWound
Flag link:
IPO Could Be Too Little, Too Early For Akebia Therapeutics
IPO Could Be Too Little, Too Early For Akebia Therapeutics
Seeking Alpha
IPOs
Akebia Therapeutics
anemia
Flag link:
Akebia Therapeutics Completes Series B
Akebia Therapeutics Completes Series B
techfinance.ca
Akebia Therapeutics
Flag link: